Chemical Name: (medrysone 1% liquifilm opthalmic) 11(beta)-Hydroxy-6(alpha)-methylpregn-4-ene-3, 20-dione.
Contains: Active: medrysone 1.0%. Preservative: benzalkonium chloride 0.004%. Inactives: LIQUIFILM® (polyvinyl alcohol) 1.4%. edetate disodium; sodium chloride; potassium chloride; sodium phosphate, monobasic; sodium phosphate, dibasic; hydroxypropyl methylcellulose; sodium hydroxide to adjust the pH; and purified water.
DOSAGE AND ADMINISTRATION
Shake well before using. Instill one drop in the conjunctival sac up to every four hours.
HMS® (medrysone) 1.0% LIQUIFILM® sterile ophthalmic suspension is supplied in plastic dropper bottles in the following sizes:
5 mL NDC 11980-074-05
10 mL NDC 11980-074-10
Note: Protect from freezing.
Adverse reactions include occasional transient stinging and burning on instillation. Increased intraocular pressure, which may be associated with optic nerve damage and defects in the visual fields, and posterior subcapsular cataract formation have been reported rarely with the use of HMS® (medrysone 1% liquifilm opthalmic) .
No Informatuion Provided.
Prolonged use of topical corticosteroids may increase intraocular pressure, with resultant glaucoma, damage to the optic nerve, and defects in visual acuity and fields of vision. However, data from 2 uncontrolled studies 1-2 indicate that in patients with increased intraocular pressure and in those susceptible to a rise in intraocular pressure upon application of topical corticosteroids, there is less effect on pressure with HMS® (medrysone 1% liquifilm opthalmic) than with dexamethasone or betamethasone.
Prolonged use of topical corticosteroids may rarely be associated with development of posterior subcapsular cataracts.
General: With prolonged use of HMS® (medrysone 1% liquifilm opthalmic) , the intraocular pressure and the lens should be examined periodically. In persistent corneal ulceration where a corticosteroid has been used, or is in use, fungal infection should be suspected.
Pregnancy Category C: Medrysone has been shown to be embryocidal in rabbits when given in doses 10 and 30 times the human dose. Medrysone was ocularly applied to both eyes of pregnant rabbits 2 drops 4 times per day on day 6 through 18 of gestation. A significant increase in early resorptions was observed in the treated rabbits. There are no adequate or well-controlled studies in pregnant women. Medrysone should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Pediatric Use: Safety and effectiveness in pediatric patients have not been established.
Overdosage will not ordinarily cause acute problems. If accidentally ingested, drink fluids to dilute.
HMS® (medrysone) is contraindicated in the following conditions:
Hypersensitivity to any of the components of the drug
HMS® (medrysone) is a synthetic corticosteroid with topical anti-inflammatory and anti-allergic activity. Corticosteroids inhibit the inflammatory response to inciting agents of mechanical, chemical, or immunological nature of edema, fibrin deposition, capillary dilation and leukocyte migration, capillary proliferation, deposition of collagen and scar formation. HMS® (medrysone) has less anti-inflammatory potency than 0.1% dexamethasone. Data from 2 uncontrolled studies 1-2 indicate that in patients with increased intraocular pressure and in those susceptible to a rise in intraocular pressure, there is less effect on pressure with HMS® (medrysone 1% liquifilm opthalmic) than with dexamethasone or betamethasone.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.